Stuart Essig

Stuart M. Essig is a healthcare executive and investor best known for his long tenure at Integra LifeSciences. Integra states that he has served on its board since joining the company in 1997, was CEO from 1997 through 2012, became chairman in 2012, served as executive chairman from February 2024 to June 2025, and returned as president and CEO effective May 1, 2026.

Before Integra, Essig spent ten years at Goldman, Sachs & Co., where he was managing director of the medical technology practice and advised medical technology, pharmaceutical, and biotechnology clients on mergers and acquisitions. Integra says that during his nearly 30-year tenure with the company, revenues grew from about $15 million to more than $1.6 billion.

Essig is Managing Partner / Managing Director of Prettybrook Partners LLC, a family office that invests in medical technology companies and has about 25 active investments, typically as a co-investor with institutional private equity. He is also a venture partner at Wellington Partners Advisory AG and serves on the boards of IDEXX Laboratories, Piper Sandler Companies, and Availity.

He received an A.B. from Princeton University’s School of Public and International Affairs, graduating magna cum laude and Phi Beta Kappa, and earned an MBA and Ph.D. in financial economics from the University of Chicago Graduate School of Business.

• Prettybrook describes its focus as “Creating value in healthcare and the life sciences,” investing in medical technology products and businesses as well as healthcare services companies.
• The firm says it “invests primarily in leveraged buyouts and venture investments where we can have significant governance impact.”
• Prettybrook’s preferred structure is to invest side-by-side with venture capital or private equity backers, especially where its healthcare network, operating experience, M&A background, and governance expertise can matter.
• Transaction types include control-oriented leveraged buyouts, restructurings / recapitalizations, staged transitions of corporate-owned entities, partnerships with strategic or financial buyers, and going-private transactions.
• Prettybrook lists targeted healthcare and medical technology focus, proprietary investment generation, post-investment value creation, transaction structuring, and exit planning as key strengths.
• Essig’s personal edge is concentrated in medtech, medical devices, healthcare services, healthcare IT, board governance, CEO succession, M&A, and scaling commercial medical-products businesses.